Core Viewpoint - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States and will present at the 23rd Annual Morgan Stanley Global Healthcare Conference in New York City on September 9, 2025 [1][2]. Company Overview - LifeStance Health was founded in 2017 and focuses on reimagining mental health care, providing both virtual and in-person outpatient services for various mental health conditions [4]. - The company employs approximately 7,700 professionals, including psychiatrists, advanced practice nurses, psychologists, and therapists, operating across 33 states with over 550 centers [4]. - LifeStance's mission is to enhance access to trusted, affordable, and personalized mental health care, aiming to help individuals lead healthier and more fulfilling lives [4]. Presentation Details - The presentation will be led by CEO Dave Bourdon and CFO Ryan McGroarty, moderated by Craig Hettenbach, and will take place at 10:00 a.m. Eastern time [2]. - The event will be webcast live and available for replay on the LifeStance Health Investor Relations website [2][3].

Personette brings to LifeStance more than 20 years of experience delivering exceptional customer experiences for some of the world's most influential brands. Currently, she serves as the CEO of Puck, a journalist-owned media platform. Previously, she served as Chief Customer Officer at the social platform X (formerly known as Twitter), overseeing global revenue, customer relationships and business operations. Prior to X, Personette was the Chief Operating Officer of Refinery29, where she oversaw the company ...

Core Viewpoint - Numinus Wellness Inc. reported significant growth in revenue for Q2 2025, driven by its focus on innovative mental health care and psychedelic-assisted therapies, although it also faced increased costs and operating losses [1][2]. Financial Performance - Total revenue for Q2 2025 reached CAD 1,512,435, marking an 83.8% increase from CAD 822,973 in Q2 2024 [2]. - Cost of revenue surged to CAD 1,007,691, a 175.7% increase from CAD 365,446 in the same quarter last year [2]. - Gross profit was CAD 504,744, reflecting a 10.3% increase from CAD 457,527 in Q2 2024, with a gross profit margin of 33.4%, down from 55.6% [2]. - Operating expenses rose to CAD 9,886,497, an 86.31% increase from CAD 5,306,523 in Q2 2024 [2]. - The company reported a comprehensive loss of CAD 7,705,397, compared to CAD 5,960,437 in the previous year [2]. Balance Sheet and Liquidity - Numinus ended the quarter with cash and cash equivalents amounting to CAD 705,631 [3]. Company Overview - Numinus Wellness Inc. is focused on developing and delivering innovative mental health care solutions, particularly through evidence-based psychedelic-assisted therapies, aiming to transform treatment for conditions like depression, anxiety, and substance use [4].

Core Insights - Numinus Wellness Inc. reported a significant increase in total revenue for Q1 2025, reaching $2,013,779, which represents a 68.3% increase compared to $1,196,629 in Q1 2024 [2] - The company achieved a gross profit of $1,021,157, marking a 121.1% increase from $461,943 in the same quarter last year, with a gross profit margin of 49.3% [2] - Operating expenses decreased by 51.1% to $2,065,596 from $4,226,850 in Q1 2024, contributing to a reduced comprehensive loss of $1,286,464 compared to $4,351,472 in the previous year [2] Financial Performance Metrics - Total Revenue: $2,013,779 for Q1 2025 vs. $1,196,629 for Q1 2024, a 68.3% increase [2] - Cost of Revenue: $992,622 for Q1 2025 vs. $734,686 for Q1 2024, a 35.1% increase [2] - Gross Profit: $1,021,157 for Q1 2025 vs. $461,943 for Q1 2024, a 121.1% increase [2] - Gross Profit Margin: 49.3% for Q1 2025 vs. 38.6% for Q1 2024, an increase of 107 basis points [2] - Operating Expenses: $2,065,596 for Q1 2025 vs. $4,226,850 for Q1 2024, a decrease of 51.1% [2] - Comprehensive Loss: ($1,286,464) for Q1 2025 vs. ($4,351,472) for Q1 2024 [2] Balance Sheet and Liquidity - Numinus ended the quarter with cash and cash equivalents of $2.0 million [3] - The financial statements were prepared in accordance with IFRS and are available on the company's Investor Relations website [3] Company Overview - Numinus Wellness Inc. focuses on innovative mental health care and the development of safe, evidence-based psychedelic-assisted therapies [4] - The company aims to transform mental health treatment by integrating psychedelic-assisted therapies into mainstream clinical practice, targeting conditions such as depression, anxiety, trauma, pain, and substance use [4]

Core Insights - Numinus Wellness Inc. reported a 16.4% increase in consolidated revenues for Q4 2024 compared to Q3 2024, driven by growth in its Cedar Clinical Research and Practitioner Training segments [3][4][15] - The company successfully transitioned to a lean operation, aligning cash flows with overhead costs, and is focused on leveraging growth opportunities in its clinical research and training businesses [3][4] Financial Performance - Total revenue for Q4 2024 was $1,155,936, up from $992,912 in Q3 2024, marking a 16.4% increase [15] - Revenue from Cedar Clinical Research increased by 17.2% to $965,799, while Practitioner Training revenue rose by 12.6% to $190,137 [4][11] - Gross margin improved to 25.3% in Q4 2024, compared to a gross margin loss of 4.6% in Q3 2024 [5][15] - Operating expenditures decreased significantly to $931,198 from $2.9 million in the previous quarter, reflecting ongoing cost containment initiatives [6][15] Operational Highlights - Cedar Clinical Research managed 18 clinical trials with 306 patient appointments in Q4 2024, an increase from 15 trials and 233 appointments in Q3 2024 [9] - The company’s Psychedelic-Assisted Therapy Training Program received approval from the state of Colorado, enhancing its position in the market [16] Corporate Updates - The company completed the sale of its wellness clinic network for US$3.53 million, leading to the classification of this segment as discontinued operations [8][19] - Leadership changes included the appointment of Michael Tan as CEO and Kelvin Yang as CFO [8] Balance Sheet and Liquidity - Numinus ended Q4 2024 with cash and cash equivalents of $2.0 million and working capital of $1.2 million [14]

Core Insights - LifeStance Health Group, Inc. is set to release its second quarter 2025 earnings on August 7, 2025, before market opening [1] - A live earnings conference call will be held on the same day at 8:30 a.m. Eastern Time to discuss the results [2] - The company provides access to a real-time audio webcast of the earnings call on its Investor Relations website [3] Company Overview - Founded in 2017, LifeStance is one of the largest providers of outpatient mental health care in the U.S., offering both virtual and in-person services [4] - The company employs approximately 7,500 mental health professionals and operates over 550 centers across 33 states [4] - LifeStance's mission focuses on improving access to affordable and personalized mental health care for individuals of all ages [4]

Core Insights - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States [3] - The company will present at the 46th Annual Goldman Sachs Healthcare Conference on June 10, 2025 [1] - The presentation will be led by CEO Dave Bourdon and CFO Ryan McGroarty, and will be available via live webcast [1][2] Company Overview - LifeStance Health was founded in 2017 and focuses on providing virtual and in-person outpatient mental health care for various age groups [3] - The company employs approximately 7,500 mental health professionals and operates over 550 centers across 33 states [3] - LifeStance aims to improve access to affordable and personalized mental health care, helping individuals lead healthier lives [3]

Core Insights - LifeStance Health has appointed Vaughn Paunovich as Chief Technology Officer, effective June 9, 2025, to lead the company's technology strategy and enhance the patient and clinician experience [1][2] - Paunovich has over 25 years of experience in healthcare technology, previously serving as EVP at Amwell and holding various leadership roles at UnitedHealth Group, including Chief Information Officer of Optum Health [2][3] - The transition follows the departure of Pablo Pantaleoni, who played a significant role in LifeStance's digital transformation since 2020 and will assist Paunovich during the transition [3] Company Overview - LifeStance Health, founded in 2017, is one of the largest providers of virtual and in-person outpatient mental healthcare in the U.S., operating over 550 centers across 33 states [4] - The company employs approximately 7,500 mental health professionals, including psychiatrists, psychologists, and therapists, with a mission to improve access to affordable and personalized mental healthcare [4]

Core Viewpoint - LifeStance Health Group, Inc. is set to release its first quarter 2025 earnings on May 7, 2025, before market opening, highlighting its position as a major player in outpatient mental health care [1]. Group 1: Earnings Release Information - LifeStance will host a live earnings conference call on May 7, 2025, at 8:30 a.m. Eastern Time to discuss the first quarter results [2]. - Participants can join the call by dialing specific domestic and international numbers and using a conference ID [2]. - A real-time audio webcast will be available on the LifeStance Investor Relations website, with related materials posted prior to the call [3]. Group 2: Company Overview - Founded in 2017, LifeStance is one of the largest providers of virtual and in-person outpatient mental health care in the U.S. [4]. - The company employs approximately 7,400 mental health professionals and operates over 550 centers across 33 states [4]. - LifeStance aims to improve access to affordable and personalized mental health care, helping individuals lead healthier lives [4].

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $22.5 million, an increase of 11% compared to $20.3 million in Q4 2023 [22][8] - U.S. NeuroStar Advanced Therapy System revenue was $3.8 million with 46 systems shipped [22][23] - U.S. treatment session revenue decreased by 14% year-over-year to $12.9 million, primarily due to the removal of Greenbrook treatment session revenues [23] - Gross margin was 66.2%, down from 77.6% in the prior year, primarily due to the inclusion of Greenbrook Clinics business [24] - Operating expenses increased by 28% to $25.8 million compared to $20.2 million in Q4 2023 [24] - Net loss for Q4 was $12.1 million or $0.33 per share, compared to a net loss of $5.4 million or $0.19 per share in the prior year [25] - EBITDA was negative $10.5 million, including approximately $10.6 million in non-recurring expenses related to the Greenbrook acquisition [25] Business Line Data and Key Metrics Changes - NeuroStar system revenue was $3.8 million, with 46 systems shipped [22][23] - U.S. clinic revenue, representing Greenbrook's revenues post-acquisition, was $4.4 million [23] Market Data and Key Metrics Changes - The company received FDA clearance for the NeuroStar system to treat adolescents aged 15 to 21, expanding the total addressable market for major depressive disorder [18] - There was an 18% increase in customer sites treating adolescent patients, now including more than half of the customer base [19] Company Strategy and Development Direction - The company aims to rapidly scale the Better Me Provider Program across its customer base, targeting over 500 sites by year-end 2025 [34][32] - The acquisition of Greenbrook TMS is seen as a transformative step, creating a leading TMS supplier and provider in the U.S. [14][15] - The company has identified significant cost synergies, capturing over 90% of the identified $22 million in annualized cost synergies by the end of 2024 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity by Q3 2025, supported by enhanced scale and operational efficiencies [41] - The company anticipates full-year revenue in the range of $145 million to $155 million for 2025, with a focus on improving utilization and expanding the SPRAVATO rollout [29][30] Other Important Information - The company raised $18.9 million in capital to support its growth trajectory [10] - The Better Me Provider Program has shown that practices implementing its standards treat three times more patients per site per quarter compared to those not in the program [13] Q&A Session Summary Question: Status of Greenbrook integration and BMP implementation - Management indicated ongoing training and implementation of BMP standards across clinics, with changes expected to continue throughout the year [46] Question: Guidance on revenue and operating expenses - The revenue guidance of $145 million to $155 million is based on contributions from both Neuronetics and Greenbrook, with a focus on improving utilization and expanding SPRAVATO [51][53] Question: Margin profile and improvement opportunities - Management acknowledged opportunities for margin improvement, particularly by eliminating underperforming clinics and optimizing operations [62] Question: SPRAVATO rollout and capital requirements - The capital outlay for SPRAVATO rollout is minimal, with inventory commitments potentially reaching $5 million [84] Question: Current productivity levels and future expectations - Current average patient treatments per day at Greenbrook are about four, with expectations to increase to five or six by the end of 2025 [88]